A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlatesAndrew W. Hahn, John W. Davis, Yao Yu et al.|British Journal of Urology|2024Cited by 4
Grade Group 1 Core Volume at Time of Biopsy Is Not Associated With Rate of Adverse Pathology at Radical ProstatectomyAlex Leonard, Justin R. Gregg, Curtis A. Pettaway et al.|JU Open Plus|2025Cited by 3